PRLD (STOCKS)
Prelude Therapeutics Incorporated
$5.360000
-0.370000 (-6.46%)
Prev close: $5.730000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Krishna Vaddi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $556.17M
- Employees
- 131
- P/E (TTM)
- -6.80
- P/B (TTM)
- 3.42
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.13 | $-0.25 | +0.1233 | +48.68% |
|
Dec 2025 (Q4)
|
$-0.20 | $-0.03 | -0.1704 | -575.68% |
|
Sep 2025 (Q3)
|
$-0.26 | $-0.37 | +0.1126 | +30.22% |
|
Jun 2025 (Q2)
|
$-0.41 | $-0.45 | +0.0383 | +8.54% |
Financial Statements
| Revenues | $22.42M |
| Benefits Costs and Expenses | $56.69M |
| Costs And Expenses | $83.61M |
| Operating Expenses | $89.82M |
| Research and Development | $69.43M |
| Other Operating Expenses | $20.39M |
| Operating Income/Loss | -$67.40M |
| Income/Loss From Continuing Operations After Tax | -$60.49M |
| Income/Loss From Continuing Operations Before Tax | -$34.26M |
| Net Income/Loss | -$60.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$60.49M |
| Net Income/Loss Available To Common Stockholders, Basic | -$60.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.73 |
| Diluted Earnings Per Share | -$0.73 |
| Basic Average Shares | 257,959,050 |
| Diluted Average Shares | 257,959,050 |
| Assets | $189.36M |
| Current Assets | $154.90M |
| Noncurrent Assets | $34.47M |
| Fixed Assets | $4.40M |
| Other Non-current Assets | $30.07M |
| Liabilities | $55.63M |
| Current Liabilities | $38.04M |
| Accounts Payable | $2.03M |
| Wages | $4.01M |
| Other Current Liabilities | $32.00M |
| Noncurrent Liabilities | $17.59M |
| Equity | $133.73M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $133.73M |
| Liabilities And Equity | $189.36M |
| Net Cash Flow From Operating Activities | -$33.26M |
| Net Cash Flow From Operating Activities, Continuing | -$33.26M |
| Net Cash Flow From Investing Activities | -$77.25M |
| Net Cash Flow From Investing Activities, Continuing | -$77.25M |
| Net Cash Flow From Financing Activities | $110.45M |
| Net Cash Flow From Financing Activities, Continuing | $110.45M |
| Net Cash Flow | -$62.00K |
| Net Cash Flow, Continuing | -$62.00K |
| Comprehensive Income/Loss | -$60.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$60.71M |
| Other Comprehensive Income/Loss | -$19.95M |